Do analysts prefer CDXS or DOMH?

Codexis currently has a consensus target price of $5.00, suggesting a potential upside of 95.31%. Given Codexis' stronger consensus rating and higher probable upside, equities analysts clearly believe Codexis is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Codexis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, CDXS or DOMH?

Dominari has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Codexis $78.09M 2.98 -$43.97M -$0.37 N/A Dominari $123.10M 0.57 -$22.43M -$4.03 N/A

Is CDXS or DOMH more profitable?

Dominari has a net margin of -31.37% compared to Codexis' net margin of -40.97%. Codexis' return on equity of -68.09% beat Dominari's return on equity. Company Net Margins Return on Equity Return on Assets Codexis -40.97% -68.09% -23.72% Dominari -31.37% -206.20% -155.26%

Do analysts recommend DOMH or AGEN?

Agenus has a consensus target price of $23.00, indicating a potential upside of 612.07%. Given Agenus' stronger consensus rating and higher probable upside, analysts plainly believe Agenus is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Agenus 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, DOMH or AGEN?

Agenus has lower revenue, but higher earnings than Dominari. Dominari is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dominari $123.10M 0.57 -$22.43M -$4.03 N/A Agenus $114.20M 1.18 $120K $1.59 2.03

Is DOMH or AGEN more profitable?

Agenus has a net margin of 50.49% compared to Dominari's net margin of -31.37%. Agenus' return on equity of -31.66% beat Dominari's return on equity. Company Net Margins Return on Equity Return on Assets Dominari -31.37% -206.20% -155.26% Agenus 50.49% -31.66% 42.71%

Do analysts prefer DOMH or FBIO?

Fortress Biotech has a consensus target price of $17.00, suggesting a potential upside of 541.51%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Fortress Biotech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is DOMH or FBIO more profitable?

Fortress Biotech has a net margin of 193.12% compared to Dominari's net margin of -31.37%. Fortress Biotech's return on equity of 109.66% beat Dominari's return on equity. Company Net Margins Return on Equity Return on Assets Dominari -31.37% -206.20% -155.26% Fortress Biotech 193.12% 109.66% 45.56%

Do analysts prefer DOMH or SGMO?

Sangamo Therapeutics has a consensus target price of $5.50, indicating a potential upside of 2,458.14%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sangamo Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75

Is DOMH or SGMO more profitable?

Dominari has a net margin of -31.37% compared to Sangamo Therapeutics' net margin of -310.81%. Dominari's return on equity of -206.20% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dominari -31.37% -206.20% -155.26% Sangamo Therapeutics -310.81% -2,662.06% -132.12%

Do analysts recommend CRIS or DOMH?

Curis currently has a consensus price target of $17.00, indicating a potential upside of 3,491.80%. Given Curis' stronger consensus rating and higher probable upside, research analysts plainly believe Curis is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curis 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, CRIS or DOMH?

Curis has higher earnings, but lower revenue than Dominari. Dominari is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Curis $9.44M 1.95 -$7.58M -$1.19 N/A Dominari $123.10M 0.57 -$22.43M -$4.03 N/A

Is CRIS or DOMH more profitable?

Dominari has a net margin of -31.37% compared to Curis' net margin of -80.29%. Curis' return on equity of 0.00% beat Dominari's return on equity. Company Net Margins Return on Equity Return on Assets Curis -80.29% N/A -181.57% Dominari -31.37% -206.20% -155.26%

Dominari (DOMH) Competitors

$3.10 -0.16 (-4.91%)

Closing price 04:00 PM Eastern

Extended Trading

$3.02 -0.09 (-2.74%)

As of 06:38 PM Eastern

Compare

DOMH vs. CDXS, AGEN, FBIO, SGMO, and CRIS

Should you buy Dominari stock or one of its competitors? MarketBeat compares Dominari with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dominari include Codexis (CDXS), Agenus (AGEN), Fortress Biotech (FBIO), Sangamo Therapeutics (SGMO), and Curis (CRIS). These companies are all part of the "biotechnology" industry.

How does Dominari compare to Codexis?

Codexis (NASDAQ:CDXS) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Codexis currently has a consensus target price of $5.00, suggesting a potential upside of 95.31%. Given Codexis' stronger consensus rating and higher probable upside, equities analysts clearly believe Codexis is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Dominari has a net margin of -31.37% compared to Codexis' net margin of -40.97%. Codexis' return on equity of -68.09% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-40.97%	-68.09%	-23.72%
Dominari	-31.37%	-206.20%	-155.26%

In the previous week, Codexis had 1 more articles in the media than Dominari. MarketBeat recorded 1 mentions for Codexis and 0 mentions for Dominari. Codexis' average media sentiment score of 0.00 equaled Dominari'saverage media sentiment score.

Company	Overall Sentiment
Codexis	Neutral
Dominari	Neutral

Dominari has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$78.09M	2.98	-$43.97M	-$0.37	N/A
Dominari	$123.10M	0.57	-$22.43M	-$4.03	N/A

78.5% of Codexis shares are owned by institutional investors. Comparatively, 42.5% of Dominari shares are owned by institutional investors. 3.5% of Codexis shares are owned by insiders. Comparatively, 55.3% of Dominari shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Codexis has a beta of 2.48, suggesting that its share price is 148% more volatile than the broader market. Comparatively, Dominari has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

Summary

Codexis beats Dominari on 10 of the 15 factors compared between the two stocks.

How does Dominari compare to Agenus?

Dominari (NASDAQ:DOMH) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

In the previous week, Agenus had 1 more articles in the media than Dominari. MarketBeat recorded 1 mentions for Agenus and 0 mentions for Dominari. Agenus' average media sentiment score of 0.47 beat Dominari's score of 0.00 indicating that Agenus is being referred to more favorably in the news media.

Company	Overall Sentiment
Dominari	Neutral
Agenus	Neutral

Agenus has a net margin of 50.49% compared to Dominari's net margin of -31.37%. Agenus' return on equity of -31.66% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dominari	-31.37%	-206.20%	-155.26%
Agenus	50.49%	-31.66%	42.71%

Agenus has a consensus target price of $23.00, indicating a potential upside of 612.07%. Given Agenus' stronger consensus rating and higher probable upside, analysts plainly believe Agenus is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Agenus has lower revenue, but higher earnings than Dominari. Dominari is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$123.10M	0.57	-$22.43M	-$4.03	N/A
Agenus	$114.20M	1.18	$120K	$1.59	2.03

Dominari has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Agenus has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

42.5% of Dominari shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 55.3% of Dominari shares are held by insiders. Comparatively, 5.5% of Agenus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Agenus beats Dominari on 14 of the 16 factors compared between the two stocks.

How does Dominari compare to Fortress Biotech?

Dominari (NASDAQ:DOMH) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Fortress Biotech has a net margin of 193.12% compared to Dominari's net margin of -31.37%. Fortress Biotech's return on equity of 109.66% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dominari	-31.37%	-206.20%	-155.26%
Fortress Biotech	193.12%	109.66%	45.56%

42.5% of Dominari shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 55.3% of Dominari shares are held by company insiders. Comparatively, 28.5% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Fortress Biotech has lower revenue, but higher earnings than Dominari. Dominari is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$123.10M	0.57	-$22.43M	-$4.03	N/A
Fortress Biotech	$63.26M	1.39	$6.82M	$3.17	0.84

Fortress Biotech has a consensus target price of $17.00, suggesting a potential upside of 541.51%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Fortress Biotech's average media sentiment score of 0.63 beat Dominari's score of 0.00 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Dominari	Neutral
Fortress Biotech	Positive

Dominari has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

Summary

Fortress Biotech beats Dominari on 13 of the 15 factors compared between the two stocks.

How does Dominari compare to Sangamo Therapeutics?

Dominari (NASDAQ:DOMH) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Sangamo Therapeutics has a consensus target price of $5.50, indicating a potential upside of 2,458.14%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Dominari has higher revenue and earnings than Sangamo Therapeutics. Dominari is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$123.10M	0.57	-$22.43M	-$4.03	N/A
Sangamo Therapeutics	$39.55M	2.25	-$122.93M	-$0.38	N/A

Dominari has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

In the previous week, Dominari's average media sentiment score of 0.00 equaled Sangamo Therapeutics'average media sentiment score.

Company	Overall Sentiment
Dominari	Neutral
Sangamo Therapeutics	Neutral

42.5% of Dominari shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 55.3% of Dominari shares are owned by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Dominari has a net margin of -31.37% compared to Sangamo Therapeutics' net margin of -310.81%. Dominari's return on equity of -206.20% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dominari	-31.37%	-206.20%	-155.26%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Summary

Sangamo Therapeutics beats Dominari on 9 of the 14 factors compared between the two stocks.

How does Dominari compare to Curis?

Curis (NASDAQ:CRIS) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Curis has a beta of 3.05, meaning that its stock price is 205% more volatile than the broader market. Comparatively, Dominari has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

In the previous week, Curis had 1 more articles in the media than Dominari. MarketBeat recorded 1 mentions for Curis and 0 mentions for Dominari. Curis' average media sentiment score of 0.00 equaled Dominari'saverage media sentiment score.

Company	Overall Sentiment
Curis	Neutral
Dominari	Neutral

Curis has higher earnings, but lower revenue than Dominari. Dominari is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	1.95	-$7.58M	-$1.19	N/A
Dominari	$123.10M	0.57	-$22.43M	-$4.03	N/A

Curis currently has a consensus price target of $17.00, indicating a potential upside of 3,491.80%. Given Curis' stronger consensus rating and higher probable upside, research analysts plainly believe Curis is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Dominari has a net margin of -31.37% compared to Curis' net margin of -80.29%. Curis' return on equity of 0.00% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	N/A	-181.57%
Dominari	-31.37%	-206.20%	-155.26%

30.0% of Curis shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 5.4% of Curis shares are held by company insiders. Comparatively, 55.3% of Dominari shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Curis beats Dominari on 10 of the 15 factors compared between the two stocks.

Get Dominari News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DOMH vs. The Competition

Export

Metric	Dominari	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$70.09M	$2.93B	$6.44B	$11.97B
Dividend Yield	N/A	1.69%	2.69%	5.32%
P/E Ratio	-0.77	17.86	23.77	23.69
Price / Sales	0.57	294.72	488.26	87.20
Price / Cash	N/A	55.54	41.39	55.53
Price / Book	0.72	3.83	9.76	6.39
Net Income	-$22.43M	$75.85M	$3.56B	$337.36M
7 Day Performance	-16.22%	-4.88%	-3.19%	-3.07%
1 Month Performance	-8.55%	-5.87%	-0.11%	0.37%
1 Year Performance	-36.21%	18.98%	25.29%	27.87%

Dominari Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DOMH Dominari	0.2428 of 5 stars	$3.10 -4.9%	N/A	-32.8%	$70.09M	$123.10M	N/A	4
CDXS Codexis	3.1051 of 5 stars	$2.60 +4.4%	$5.00 +92.3%	+20.2%	$226.33M	$70.39M	N/A	250
AGEN Agenus	2.0389 of 5 stars	$3.32 +6.8%	$14.50 +336.7%	-39.8%	$129.51M	$114.20M	2.09	440	News Coverage
FBIO Fortress Biotech	3.9462 of 5 stars	$2.69 -1.8%	$17.00 +532.0%	+49.7%	$91.02M	$63.26M	0.85	170
SGMO Sangamo Therapeutics	1.9965 of 5 stars	$0.19 +6.2%	$5.50 +2,871.4%	-57.2%	$72.21M	$39.55M	N/A	480	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DOMH) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dominari (DOMH) Competitors